Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.
Lancet
; 388(10045): 661-72, 2016 Aug 13.
Article
in En
| MEDLINE
| ID: mdl-27375040
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Vision, Ocular
/
Genetic Therapy
/
Blindness
/
Dependovirus
/
Cis-trans-Isomerases
/
Mutation
/
Occipital Lobe
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Child
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet
Year:
2016
Type:
Article